Inflammatory arthritis following ustekinumab treatment for psoriasis: a report of two cases.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 23278559.
- Also identified by DOI 10.1111/j.1365-2133.2012.11206.x.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Psoriasis is a chronic inflammatory skin condition, characterized by T-helper (Th) 1 and Th17 cell activation. Ustekinumab is a fully human immunoglobulin G1κ monoclonal antibody that targets the common p40 subunit that is shared by both interleukin (IL)-12 and IL-23, consequently inhibiting T-cell differentiation along both Th1 and Th17 pathways. This is a report of two patients who developed psoriatic arthritis during ustekinumab treatment for psoriasis. Neither patient had a personal or family history of arthritis.
Medical subject headings
- Antibodies, Monoclonal, Humanized
- Arthritis, Psoriatic
- Dermatologic Agents
- Psoriasis